@Eyeman
Last two paragraphs says it all
The stock market has played havoc with a number of biotech stocks, setting up deals like this as well as GSK’s $5 billion acquisition of Tesaro, which found out the hard way just how tough commercialization work can be. Those tumbling stocks now offer an opportunity for buyers who have been waiting to beef up their pipelines. And it’s one reason why many analysts expect M&A to be a dominant theme in biopharma this year.
Interesting article, page-3
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.82M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
